BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23996743)

  • 21. p73 Overexpression and angiogenesis in human colorectal carcinoma.
    Guan M; Peng HX; Yu B; Lu Y
    Jpn J Clin Oncol; 2003 May; 33(5):215-20. PubMed ID: 12865464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and clinical implications of P53, P63, and P73 protein in malignant tumor of the parotid gland.
    Yong M; Yang L; Suyila Q; Han W; Yuan H; Zhao C; Su X
    Turk J Med Sci; 2014; 44(5):875-82. PubMed ID: 25539561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity.
    Ory B; Ellisen LW
    Oncotarget; 2011 Mar; 2(3):259-64. PubMed ID: 21436470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One, two, three--p53, p63, p73 and chemosensitivity.
    Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
    Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
    Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
    Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation of p63 and p73 expression.
    Waltermann A; Kartasheva NN; Dobbelstein M
    Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of p53 family members and CD44 in oral squamous cell carcinoma (OSCC) in relation to tumorigenesis.
    Bidaud P; Chasle J; Sichel F; Rousseau S; Petit P; Pottier D; Picquenot JM; Louis MY; Lechevrel M
    Histol Histopathol; 2010 Mar; 25(3):331-9. PubMed ID: 20054805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis.
    Li CW; Shi L; Zhang KK; Li TY; Lin ZB; Lim MK; McKeon F; Xian W; Wang de Y
    J Allergy Clin Immunol; 2011 Mar; 127(3):765-72.e1-2. PubMed ID: 21269671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From p63 to p53 across p73.
    Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G
    FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
    Venkatanarayan A; Raulji P; Norton W; Flores ER
    Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural diversity of p63 and p73 isoforms.
    Osterburg C; Dötsch V
    Cell Death Differ; 2022 May; 29(5):921-937. PubMed ID: 35314772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure.
    Gwosdz C; Balz V; Scheckenbach K; Bier H
    Adv Otorhinolaryngol; 2005; 62():58-71. PubMed ID: 15608418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
    Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
    Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
    J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 Family isoforms.
    Bourdon JC
    Curr Pharm Biotechnol; 2007 Dec; 8(6):332-6. PubMed ID: 18289041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.
    Marabese M; Marchini S; Marrazzo E; Mariani P; Cattaneo D; Fossati R; Compagnoni A; Signorelli M; Moll UM; Codegoni AM; Broggini M
    Eur J Cancer; 2008 Jan; 44(1):131-41. PubMed ID: 18039564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 family members and human cancers.
    Bénard J; Douc-Rasy S; Ahomadegbe JC
    Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
    Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI
    Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.